- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Leerink Swann Upgrades Merck To Outperform
Recent Articles by BenzingaStaff3
- Benzinga’s News Roundup (NXY, PALM, TTEK, PERY, OSIP)
- Benzinga’s Top Pre-Market Losers (SPWRA, PALM, ZION, RFMD, GOOG)
- Benzinga’s Top Pre-Market Gainers (MDTH, LYG, BBY, GNVC, BIDU)
- GameStop Corp. (NYSE: GME) Surged After Results
- HSBC Holdings And athenahealth Downgraded
Analyst Color
- JPMorgan Raises Its Estimates For Intel (INTC, JPM)
- Metabolix, Inc. (MBLX) Maintains Market Weight Rating
- Brean Murray Carret & Co. Believes Pullback In Bruker Represents Opportunity (BRKR)
- EnerNOC, Inc. (ENOC) Maintains Overweight Rating
- Stifel Nicolaus Maintains Hold On Palm Shares (PALM)
Upgrades
- Standpoint Research Initiates Coverage On Verizon & ATT With Buy Ratings (VZ, T)
- Benzinga’s Top Upgrades (TTEK, ETE, CPSI)
- Janney Montgomery Upgrades TTEK On Valuation
- Corning (GLW) Upgraded
- Standpoint Initiates GameStop With A Buy (GME)
Price Target
- Stern Agee Raises Shoe Carnival (SCVL) Price Target To $27
- Operating Profits At FedEx (FDX) May Rise 9% Annually
- Craig-Hallum Maintains LookSmart (LOOK) Buy Rating
- Research In Motion Limited’s (RIMM) Coverage Initiated With Buy Rating And $96 Price Target
- PALM’s Solvency At Risk
Trading Ideas
- Fast Money Picks For March 22nd (MHS, CVS)
- Cramer Recommends Sonus Networks As A Speculative Play (SONS)
- Carter Worth Says Best Buy Losing Momentum (BBY)
- Biotech Stock Mailbag: Generex (PFE, MNKD)
- Look To Add Short Exposure Going Into Next Week
Analyst Ratings
Posted on 11/09/09 at 9:00am by BenzingaStaff3
Leerink Swann has upgraded Merck (NYSE: MRK) from Market Perform to Outperform. Leerink says near-term risks are already priced into the stock and Leerink thinks the long-term risk/reward is very favorable for investors.
Leerink recommends investors use near-term liquidity to build or add to an existing position. Merck closed at $32.59 on Friday. Leerink's price target on MRK, is $38, presenting 17% upside from its current price.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Non-Drowsy CLARITIN(R) Partners with Kara DioGuardi, Judge on TV's Hottest Show, to Collect Inspirational Stories from Allergy Sufferers Across America
- This Healthcare ETF (XLV) Is Seeing Above Average Call Buying
- Benzinga’s News Roundup (PEP, ALKS, MRK)
- Merck To Continue Its M&A Spree (MRK, MIL)
- Overhang On Merck & Company (MRK) Lifted By IMPROVE-IT Update
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
